Bird's nest acid composition and cosmetic with effects of tightening, fading wrinkles and brightening skin color

Abstract

The invention relates to the field of cosmetics, in particular to a sialic acid composition with the effects of tightening, fading wrinkles and brightening the skin color and cosmetics. The invention relates to a sialic acid composition with the effects of tightening, fading wrinkles and brightening skin. The sialic acid composition comprises a saussurea extract and sialic acid, in the sialic acid composition, the mass ratio of sialic acid to the abelmoschus esculentus extract is (0.5: 1)-(1: 2.5). In the sialic acid composition, the mass ratio of sialic acid to the millettia extract is 0.5: 1-1: 2.5, the sialic acid and the millettia extract can form a stable synergistic effect system under the ratio, and the effect of the sialic acid composition is obviously superior to that of a single component or combination of other ratios. By activating skin cell AQP3 aquaporin, water permeation is enhanced, and the synthesis efficiency of fibroblast collagen I is improved in a targeted manner; the anti-aging and firming effects and the skin color brightening effects of the composition are improved.

Description

Technical Field

[0001] This application relates to the field of cosmetics, and more specifically, to a sialic acid composition and cosmetic having firming, wrinkle-reducing, and skin-brightening effects. Background Technology

[0002] Sialic acid, scientifically known as N-acetylneuraminic acid, is a naturally occurring carbohydrate. It was initially isolated from submandibular gland mucin, hence its name. Sialic acid typically exists in the form of oligosaccharides, glycolipids, or glycoproteins.

[0003] Currently, there is limited research and development on the application of sialic acid in cosmetics. Summary of the Invention

[0004] The purpose of this application is to provide a sialic acid composition and cosmetic with firming, wrinkle-reducing, and skin-brightening effects.

[0005] In one aspect, this application provides a sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects.

[0006] The sialic acid composition includes:

[0007] The ingredients include chrysanthemum extract and sialic acid; in the sialic acid composition, the mass ratio of sialic acid to chrysanthemum extract is 0.5:1 to 1:2.5.

[0008] In the above technical solution, the various components in the composition synergistically enhance each other's effects. For the first time, sialic acid (N-acetylneuraminic acid) is combined with chrysanthemum extract in a specific ratio to form an active system with targeted anti-wrinkle effects. This system achieves specific wrinkle improvement through a dual-action mechanism.

[0009] On the one hand, sialic acid can specifically activate the AQP3 aquaporin on the surface of human skin keratinocytes and dermal fibroblasts, significantly enhancing the skin's deep moisture penetration and water retention capacity, laying the foundation for skin hydration to improve wrinkles;

[0010] The aforementioned human experimental data clearly demonstrate that the specific ratio of sialic acid and chrysanthemum extract can achieve an anti-wrinkle effect far exceeding that of a single ingredient through the synergistic effect of "enhanced moisture penetration and wrinkle improvement," reflecting the specificity and inventiveness of the composition of this invention and solving the technical pain point of traditional anti-wrinkle ingredients having "single effect and limited improvement."

[0011] In other embodiments of this application, the amount of chrysanthemum extract added to the composition is 2% to 5% by mass percentage;

[0012] Optionally, the amount of sialic acid added to the composition is 1% to 2% by weight.

[0013] In other embodiments of this application, the composition further includes at least one of carnosine, conocycline, ergothioneine, acetyl hexapeptide-8, and caffeine.

[0014] In the above technical solution, by simultaneously forming a complex with sialic acid, conopodyne, carnosine, conopodyne cyclic peptide, ergothioneine, acetyl hexapeptide-8, etc., the formation of SNARE complex is inhibited, blocking the transmission of muscle contraction signals; thus, the anti-wrinkle effect is further improved; thereby, a triple anti-wrinkle synergistic system can be achieved; and the anti-aging efficacy of the composition is greatly enhanced.

[0015] In other embodiments of this application, optionally, the amount of carnosine added to the composition is 0.1% to 1% by mass percentage;

[0016] In other embodiments of this application, optionally, the amount of conocycline added to the composition is 3% to 5% by mass percentage;

[0017] In other embodiments of this application, optionally, the amount of ergothioneine added to the composition is 0.01% to 0.05% by mass percentage;

[0018] In other embodiments of this application, optionally, the amount of acetyl hexapeptide-8 added to the composition is 0.05% to 0.08% by mass percentage;

[0019] In other embodiments of this application, optionally, the amount of caffeine added to the composition is 0.5% to 1% by mass.

[0020] In other embodiments of this application, the sialic acid composition comprises, by weight percentage: 2-5% chrysanthemum extract, 1-2% sialic acid, 0.1-1% carnosine, 3-5% conocycline, 0.01-0.05% ergothioneine, 0.05-0.08% acetyl hexapeptide-8, 0.5%-1% caffeine, 5-15% moisturizer, 0.1-1% antioxidant, 0.1-1% thickener, 5-25% emollient, 1-5% emulsifier, 0.05-0.5% pH adjuster, 0.01-0.1% chelating agent, and the balance being water.

[0021] In other embodiments of this application, the moisturizer includes at least one of glycerin, butylene glycol, 1,3-propanediol, or 1,2-hexanediol.

[0022] In other embodiments of this application, the antioxidant includes at least one of p-hydroxyacetophenone or tocopheryl acetate.

[0023] In other embodiments of this application, the thickener includes: ammonium acryloyldimethyl taurate / VP copolymer.

[0024] In other embodiments of this application, the emollient includes at least one of the following: shea butter, squalane, caprylic / capric triglyceride, polydimethylsiloxane, or cetearyl alcohol.

[0025] In other embodiments of this application, the emulsifier includes at least one of PEG-40 stearate, PEG-100 stearate, or glyceryl stearate.

[0026] In other embodiments of this application, the pH adjuster includes arginine.

[0027] In other embodiments of this application, the chelating agent includes disodium EDTA.

[0028] Secondly, this application provides cosmetics comprising the sialic acid composition provided in any of the first aspects above, which has the effects of firming, reducing wrinkles, and brightening skin tone. Detailed Implementation

[0029] To make the objectives, technical solutions, and advantages of the embodiments of this application clearer, the technical solutions in the embodiments of this application will be clearly and completely described below. Obviously, the described embodiments are some embodiments of this application, but not all embodiments.

[0030] Therefore, the following detailed description of the embodiments of this application is not intended to limit the scope of the claimed application, but merely to illustrate selected embodiments of the application. All other embodiments obtained by those skilled in the art based on the embodiments of this application without inventive effort are within the scope of protection of this application.

[0031] In one aspect, this application provides a sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects.

[0032] The sialic acid composition includes:

[0033] The ingredients include chrysanthemum extract and sialic acid; in the sialic acid composition, the mass ratio of sialic acid to chrysanthemum extract is 0.5:1 to 1:2.5.

[0034] In the above technical solution, the various components in the composition synergistically enhance each other's effects. For the first time, sialic acid (N-acetylneuraminic acid) is combined with chrysanthemum extract in a specific ratio to form an active system with targeted anti-wrinkle effects. This system achieves specific wrinkle improvement through a dual-action mechanism.

[0035] On the one hand, sialic acid can specifically activate the AQP3 aquaporin on the surface of human skin keratinocytes and dermal fibroblasts, significantly enhancing the skin's deep moisture penetration and water retention capacity, laying the foundation for skin hydration to improve wrinkles;

[0036] Further optionally, in some embodiments of this application, the amount of *Chrysanthemum indicum* extract added to the composition, by weight percentage, is 2% to 5%. Exemplarily, in some embodiments of this application, the amount of *Chrysanthemum indicum* extract added to the composition, by weight percentage, is 2%, 2.2%, 2.5%, 2.8%, 2.9%, 3.0%, 3.2%, 3.3%, 3.5%, 3.8%, 4.0%, 4.2%, 4.3%, 4.5%, 4.8%, 5%, or a range between any two of the aforementioned values.

[0037] Further optionally, in some embodiments of this application, the amount of sialic acid added to the composition, by weight percentage, is 1% to 2%. Exemplarily, in some embodiments of this application, the amount of sialic acid added to the composition, by weight percentage, is 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, or a range between any two of the aforementioned values.

[0038] Further, optionally, in some embodiments of this application, the composition further includes at least one of carnosine, conocycline, ergothioneine, acetyl hexapeptide-8, and caffeine.

[0039] In the above technical solution, the various components in the composition synergistically enhance each other. For the first time, sialic acid (N-acetylneuraminic acid) and chamomile extract have found a "golden ratio"—when the two are combined at a mass ratio of 1:2.5, the effect far surpasses that of simple mixing. By activating the AQP3 aquaporin in skin cells, it enhances moisture penetration and targets and improves the collagen I synthesis efficiency of fibroblasts, thus enhancing the anti-aging, firming, and skin-brightening effects of the composition. Simultaneously, sialic acid forms a complex with conopodide, carnosine, conopodyl cyclic peptide, pro-xylene, ergothioneine, and acetyl hexapeptide-8 to inhibit the formation of the SNARE complex and block muscle contraction signal transmission, further improving the anti-wrinkle effect. Furthermore, the synergistic effect between the complexes provides excellent antioxidant and anti-aging effects, thereby achieving a triple anti-wrinkle synergistic system and greatly enhancing the anti-aging efficacy of the composition.

[0040] Further optionally, in some embodiments of this application, the amount of carnosine added to the composition is 0.1% to 1% by mass percentage.

[0041] For example, in some embodiments of this application, the amount of carnosine added to the composition, by mass percentage, is 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, or any two of the aforementioned values.

[0042] Further optionally, in some embodiments of this application, the amount of conocyclopeptide added to the composition is 3% to 5% by mass percentage.

[0043] For example, in some embodiments of this application, the amount of conocyclopeptide added to the composition, by mass percentage, is 3%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5%, or any range between any two of the aforementioned values.

[0044] Further optionally, in some embodiments of this application, the amount of ergothioneine added to the composition is 0.01% to 0.05% by mass percentage.

[0045] For example, in some embodiments of this application, the amount of ergothionein added to the composition, by mass percentage, is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, or any two of the aforementioned values.

[0046] Further optionally, in some embodiments of this application, the amount of acetyl hexapeptide-8 added to the composition is 0.05% to 0.08% by mass percentage;

[0047] For example, in some embodiments of this application, the amount of acetyl hexapeptide-8 added to the composition, by mass percentage, is 0.05%, 0.06%, 0.07%, 0.08%, or any range between two of the aforementioned values.

[0048] Further optionally, in some embodiments of this application, the amount of caffeine added to the composition is 0.5% to 1% by mass percentage.

[0049] For example, in some embodiments of this application, the amount of caffeine added to the composition, by weight percentage, is 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 1%, or any two of the aforementioned values.

[0050] Further optionally, in some embodiments of this application, the sialic acid composition comprises, by weight percentage: 2-5% chrysanthemum extract, 1-2% sialic acid, 0.1-1% carnosine, 3-5% conocycline, 0.01-0.05% ergothioneine, 0.05-0.08% acetyl hexapeptide-8, 0.5%-1% caffeine, 5-15% humectant, 0.1-1% antioxidant, 0.1-1% thickener, 5-25% emollient, 1-5% emulsifier, 0.05-0.5% pH adjuster, 0.01-0.1% chelating agent, and the balance being water.

[0051] In the above technical solution, by combining conospirin and acetyl hexapeptide-8 within the above-mentioned content range, the formation of SNARE complex can be inhibited and the transmission of muscle contraction signals can be blocked. Human experiments (VISIA-CR detection) show that this compound system can improve the area of ​​crow's feet wrinkles by 14.67% and the area of ​​nasolabial folds by 13.49%, which is significantly better than the control group that did not use compound peptides and used single peptides alone. Finally, a triple anti-wrinkle synergistic system is formed, which greatly enhances the anti-aging efficacy of the composition and solves the problem of activity decay of traditional peptide systems.

[0052] Exemplary examples, in some embodiments of this application, the sialic acid composition, by weight percentage, comprises: 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, or any two of the aforementioned values ​​of *Chrysanthemum indicum* extract; 1%, 1.5%, 2%, or any two of the aforementioned values ​​of sialic acid; 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, or any two of the aforementioned values ​​of carnosine; 3%, 3.5%, 4%, 4.5%, 5%, or any two of the aforementioned values ​​of conocycline; and 0.01%, 0.02%, 0.03%, 0.04%. Ergothioneine at 0.05%, 0.045%, 0.05%, or any two of the aforementioned values; Acetyl hexapeptide-8 at 0.05%, 0.055%, 0.06%, 0.065%, 0.07%, 0.075%, 0.08%, or any two of the aforementioned values; Caffeine at 0.5%, 0.52%, 0.55%, 0.58%, 0.6%, 0.62%, 0.65%, 0.68%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 1%, or any two of the aforementioned values; 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%. Moisturizers at concentrations of 10.5%, 11%, 12%, 13%, 14%, 15%, or any two of the aforementioned values; antioxidants at concentrations of 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, or any two of the aforementioned values; thickeners at concentrations of 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, or any two of the aforementioned values; and thickeners at concentrations of 5%, 6%, 8%, 10%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, or any two of the aforementioned values. Emollients in the range of any two values; emulsifiers in the range of 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, or any two of the aforementioned values; pH adjusters in the range of 0.05%, 0.06%, 0.08%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, or any two of the aforementioned values; chelating agents in the range of 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, or any two of the aforementioned values, and the balance being water.

[0053] Further optionally, in some embodiments of this application, the moisturizer includes at least one of glycerin, butylene glycol, 1,3-propanediol, or 1,2-hexanediol.

[0054] Further, optionally, in some embodiments of this application, the antioxidant includes at least one of p-hydroxyacetophenone or tocopheryl acetate.

[0055] Further optionally, in some embodiments of this application, the thickener includes: ammonium acryloyldimethyl taurate / VP copolymer.

[0056] Further optionally, in some embodiments of this application, the emollient includes at least one of: shea butter, squalane, caprylic / capric triglyceride, polydimethylsiloxane, or cetearyl alcohol.

[0057] Further optionally, in some embodiments of this application, the emulsifier includes at least one of PEG-40 stearate, PEG-100 stearate, or glyceryl stearate.

[0058] Further, optionally, in some embodiments of this application, the pH adjuster includes arginine.

[0059] Further, optionally, in some embodiments of this application, the chelating agent includes: disodium EDTA.

[0060] In the above technical solution, under the premise of forming a specific golden ratio of 0.5:1 to 1:2.5 (mass ratio) between sialic acid and chrysanthemum extract, the skin's AQP3 aquaporin is specifically activated to enhance water penetration and water retention capacity, laying a hydration foundation for wrinkle improvement. On the other hand, human experiments show that the compound system has a much greater effect on improving the area and number of wrinkles at the corners of the eyes and nasolabial folds than the control group that used the same dose of sialic acid or chrysanthemum extract alone. Through the synergistic effect of "enhanced water penetration and wrinkle improvement", the pain point of the single action of traditional anti-wrinkle ingredients is solved, thereby effectively improving the anti-aging effect.

[0061] Furthermore, in the above technical solution, sialic acid and chrysanthemum extract are compounded at a ratio of 0.5:1 to 1:2.5 (by mass) to form a targeted anti-wrinkle active system. This ratio has a significantly better synergistic effect than other ratios or single ingredients. On the one hand, sialic acid can specifically activate the skin's AQP3 aquaporin to enhance water penetration and water retention, laying a hydration foundation for wrinkle improvement. On the other hand, human experiments show that this compound system has a much better effect on improving the area and number of wrinkles at the corners of the eyes and nasolabial folds than the control group that used the same dose of sialic acid or chrysanthemum extract alone. The synergistic effect of "enhanced water penetration - wrinkle improvement" solves the pain point of the single effect of traditional anti-wrinkle ingredients.

[0062] Furthermore, the aforementioned sialic acid composition, which has the effects of firming, reducing wrinkles, and brightening skin tone, also contains sialic acid in combination with conotoxin, carnosine, conocyclic peptide, ergothioneine, and acetyl hexapeptide-8 (by weight percentage, the sialic acid composition includes: 2-5% chamomile extract, 1-2% sialic acid, 0.1-1% carnosine, 3-5% conocyclic peptide, 0.01-0.05% ergothioneine, 0.05-0.08% acetyl hexapeptide-8, and 0.5%-1% caffeine). A complex is formed in which conospirin and acetyl hexapeptide-8, when combined within the above-mentioned content range, can inhibit the formation of the SNARE complex and block the transmission of muscle contraction signals. Human experiments (VISIA-CR detection) show that this complex system can improve the area of ​​crow's feet wrinkles by 14.67% and the area of ​​nasolabial folds by 13.49%, which is significantly better than the control group that did not use the complex peptide and used a single peptide alone. Finally, a triple anti-wrinkle synergistic system is formed, which greatly enhances the anti-aging efficacy of the composition.

[0063] In other embodiments of this application, the moisturizer includes at least one of glycerin, butylene glycol, or 1,2-hexanediol.

[0064] For example, in some embodiments of this application, the moisturizer selected is any one of glycerin, butylene glycol, or 1,2-hexanediol. Alternatively, in some embodiments of this application, the moisturizer selected is a mixture of glycerin, butylene glycol, or 1,2-hexanediol; or in some embodiments of this application, the moisturizer selected is a mixture of glycerin and butylene glycol; the content of each component in the mixture can be arbitrarily selected.

[0065] In other embodiments of this application, the antioxidant includes at least one of p-hydroxyacetophenone or tocopheryl acetate.

[0066] For example, in some embodiments of this application, the antioxidant selected is either p-hydroxyacetophenone or tocopherol acetate. Alternatively, in some embodiments of this application, the antioxidant selected is a mixture of p-hydroxyacetophenone and tocopherol acetate; the content of each component in the mixture can be arbitrarily selected.

[0067] In other embodiments of this application, the thickener includes: ammonium acryloyldimethyl taurate / VP copolymer.

[0068] In other embodiments of this application, the emollient includes at least one of the following: shea butter, squalane, caprylic / capric triglyceride, polydimethylsiloxane, or cetearyl alcohol.

[0069] For example, in some embodiments of this application, the emollient is selected from any one of shea butter, squalane, caprylic / capric triglyceride, polydimethylsiloxane, or cetearyl alcohol. Alternatively, in some embodiments of this application, the emollient is selected from a mixture of squalane and shea butter; or in some embodiments of this application, the emollient is selected from a mixture of shea butter, squalane, polydimethylsiloxane, and cetearyl alcohol; the content of each component in the above mixture can be arbitrarily selected.

[0070] In other embodiments of this application, the emulsifier includes at least one of PEG-40 stearate, PEG-100 stearate, or glyceryl stearate.

[0071] For example, in some embodiments of this application, the emulsifier is selected from any one of PEG-40 stearate, PEG-100 stearate, or glyceryl stearate. Alternatively, in some embodiments of this application, the emulsifier is selected from a mixture of PEG-40 stearate and PEG-100 stearate; or in some embodiments of this application, the emulsifier is selected from a mixture of glyceryl stearate and PEG-100 stearate; the content of each component in the above mixture can be arbitrarily selected.

[0072] In other embodiments of this application, the pH adjuster includes arginine.

[0073] In other embodiments of this application, the chelating agent includes disodium EDTA.

[0074] Secondly, some embodiments of this application provide a cosmetic product comprising the sialic acid composition provided in any of the first aspects above, which has the effects of firming, reducing wrinkles, and brightening skin tone.

[0075] The features and performance of this application will be further described in detail below with reference to embodiments:

[0076] Example 1

[0077] A sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects is provided, the composition and mass percentage of which are shown in Table 1 below.

[0078] Table 1

[0079]

[0080]

[0081] The preparation methods of the above compositions are as follows:

[0082] (1) Add water, humectant, thickener, chelating agent and antioxidant (p-hydroxyacetophenone) to the emulsification pot according to the weight parts in Table 1, stir and heat to 80-85℃, and stir until a completely dissolved transparent solution is obtained.

[0083] (2) Add the emollient, emulsifier, and antioxidant (tocopheryl acetate) to the oil pan according to the weight ratio, and heat until completely dissolved;

[0084] (3) Add the materials in the oil pot to the emulsifying pot, turn on the homogenizer, and homogenize until a milky white and uniform emulsion is formed.

[0085] (4) Cool down to 40-45℃ and add the plant extract, skin conditioner and pH adjuster to the emulsifying pot in the order of weight and stir evenly.

[0086] The performance of the composition samples provided in each embodiment and comparative example was tested.

[0087] 1. Skin elasticity efficacy test

[0088] (1) Skin elasticity R2 test

[0089] The test was conducted using a Cutometer MPA580 (Courage & Khazaka, Germany) skin elasticity tester.

[0090] The specific testing steps are as follows:

[0091] Thirty healthy volunteers aged 30-55 years were selected and randomly divided into 5 groups of 6 people each. (The 5 groups were designated as Group 1, Group 2, Group 3, Group 4, and Group 5 respectively; each group used the samples from Example 1, Example 2, Example 3, Example 4, and Comparative Example 1. All 6 volunteers in each group used the same sample from either Example 1 or Comparative Example 1, and the average value was taken).

[0092] Volunteers in each group washed their faces and dried their eye area. In an environment with a temperature of 25±0.5℃ and a relative humidity of 50±2%, the Cutometer MPA580 was used to test the skin elasticity R2 value of the cheeks of each group of volunteers before the experiment (R2 is the total elasticity, which represents the degree to which the skin can recover within one cycle after being deformed by negative pressure. The larger the value, the greater the elasticity. The closer it is to 1, the better the skin elasticity).

[0093] Every morning after washing their faces, volunteers in each group applied the corresponding composition from each example or comparative example to their faces and spread it evenly. This was done once daily, with each application being 1.5g. The volunteers in each group applied the compositions for 60 days. The control group underwent the same experimental procedure, except that an equal volume of physiological saline was used instead of the composition. On days 30 and 60 of the application experiment, 6 hours after applying the composition or physiological saline, volunteers in each group were tested using a Cutometer (MPA580) at an environment of 25±0.5℃ and 50±2% relative humidity. The average R2 value of skin elasticity on the cheeks of each group and the percentage increase in R2 value are shown in Table 34. The percentage increase in R2 value was calculated as: (R2 value on day 28 of the experiment / R2 value before the experiment) / R2 value before the experiment × 100%.

[0094] The test results are shown in Table 2 below.

[0095] Table 2

[0096] Example 1 Example 2 Example 3 Example 4 Comparative Example 1 R² value before experiment 0.47±0.01 0.47±0.01 0.46±0.01 0.46±0.01 0.45±0.01 R2 value on day 28 0.52±0.01 0.53±0.01 0.52±0.01 0.53±0.01 0.47±0.01 Improvement rate 10.63％ 12.76％ 13.04％ 15.22％ 4.44％

[0097] As can be seen from the test results in Table 2 above, the improvement rates of the composition samples provided in Examples 1-4 are all significantly higher than those in Comparative Example 1. This demonstrates that the solutions of this application can effectively improve skin elasticity.

[0098] Furthermore, as can be seen from the above experimental data, the composition provided in this application embodiment improves the skin elasticity R2 value by 10.63% to 15.22%; the improvement effect is significant.

[0099] 2. Skin firmness F4 test

[0100] (1) Instruments used:

[0101] The Cutometer dual MPA580 skin elasticity tester was used for testing. Its principle is based on the "suction-stretching" mechanism: a specific negative pressure is generated on the surface of the test area on the subject's cheek, drawing the skin into the instrument's dedicated test probe; through the non-contact optical system (including light emitter and receiver) inside the probe, the depth of skin being drawn in is measured—the ratio of emitted light to received light is directly proportional to the depth of skin absorption; the optical signal is analyzed using the MPA's accompanying software to calculate the skin firmness F4 value (note: the lower the F4 value, the higher the degree of skin firmness).

[0102] (1) Specific testing methods:

[0103] Subject selection

[0104] Thirty healthy men and women aged 35-60 years participated in the study. Their skin exhibited fine lines or wrinkles, with crow's feet meeting the Skinning Atlas standards of 1-5. They were randomly divided into five groups of six participants each. These groups were designated Group 1, Group 2, Group 3, Group 4, and Group 5. Each group used samples from Example 1, Example 2, Example 3, Example 4, and Comparative Example 1, respectively. All six volunteers within each group used the same sample from either Example 1 or Comparative Example 1. The average value was then calculated.

[0105] The entire experiment was conducted in a standard constant temperature and humidity environment (temperature 21℃±1℃, humidity 50%RH±10%).

[0106] For the skin firmness F4 test, the experimental period was 28 days (D0 was the initial test date, and D28 was the final test date). A "parallel control" method was used, with subjects randomly assigned one cheek as the test side (applied with the samples from each embodiment or comparative example) and the other side as the control side (unapplied). Subjects were required to use the product twice daily and keep a usage diary. Testing was conducted only at two time points: D0 (baseline period, initial F4 values ​​were collected on both cheeks) and D28 (final period, repeated collection under the same environment and location), using a Cutometer dual skin elasticity tester. Before operating the MPA580, calibrate the instrument and mark detection points symmetrically on the cheek. Place the probe against the marked points and activate the instrument to generate negative pressure. Record the emitted light / received light ratio and calculate the F4 value using software. Measure each detection point three times and take the average value. Record the data. Since a lower F4 value indicates higher firmness, when the F4 change value on the experimental side is significantly lower than that on the control side, the increase rate of skin firmness F4 value is calculated as: (Skin firmness F4 value on day 28 of the experiment / Skin firmness F4 value before the experiment) / Skin firmness F4 value before the experiment × 100%. This determines the firming effect of the comparative sample in the example.

[0107] The test results are shown in Table 3.

[0108] Table 3

[0109] Example 1 Example 2 Example 3 Example 4 Comparative Example 1 F4 value before experiment 6.17±0.12 6.18±0.12 6.15±0.12 6.18±0.12 6.17±0.12 F4 value on day 28 5.47±0.12 5.47±0.12 5.45±0.12 5.47±0.12 5.93±0.12 Improvement rate 11.34％ 11.48％ 11.38％ 11.49％ 3.89％

[0110] As can be seen from the above experimental data, the improvement rate of each embodiment is higher than that of the comparative embodiment, which shows that the skin firming effect of the embodiments of this application is significantly improved.

[0111] 3. Anti-wrinkle efficacy tests of the compositions in various embodiments and comparative examples.

[0112] Testing Instruments and Principles: The VISIA facial image analyzer is used. Relying on advanced optical imaging, RBX technology and software technology, it can quantitatively analyze the characteristics of skin wrinkles and accurately capture indicators such as the area ratio of wrinkles in the corner of the eye, providing data support for the evaluation of anti-wrinkle efficacy. In addition, it references the database of international authoritative skin companies to improve the reference value of diagnostic results.

[0113] Subject population and sites: The subject population consisted of 30 healthy subjects (4 males and 26 females, aged 36-60 years, mean age 49.52±1.23 years). Subjects were required to meet the inclusion criteria of wrinkles at the corners of the eyes according to the SKINAGING ATLAS grade 1-5. Subjects with skin diseases or high allergies were excluded. The test sites were the left and right sides of the subjects' cheeks (including the corners of the eyes), which served as the test side (applied to the example or comparative sample) and the control side (untreated).

[0114] The participants were randomly divided into 5 groups, with 6 people in each group. (The 5 groups were designated as Group 1, Group 2, Group 3, Group 4, and Group 5 respectively; each group used the samples from Example 1, Example 2, Example 3, Example 4, and Comparative Example 1. All 6 volunteers in each group used the same sample from either Example 1 or Comparative Example 1, and the average value was taken).

[0115] Testing environment and cycle: The entire testing process is conducted in a standard environment with a temperature of 20.3℃-21.8℃ and a humidity of 43.0%RH-60%RH. Before the test, the subject needs to sit quietly in this environment for 30 minutes and wipe the skin dry with a dry facial tissue. The testing cycle is 28 days, with two key time points set: D0 (baseline period) and D28 (end period). The testing of crow's feet is only carried out at these two time points.

[0116] Specific testing steps:

[0117] Instrument preparation: Before testing, VISIA instruments should be calibrated and adjusted to ensure that functions such as optical imaging are accurate and meet testing requirements.

[0118] Location marking: Mark detection points symmetrically on the left and right cheeks and corners of the eyes of the subject, avoiding skin blemishes, and ensure that the D0 and D28 detection points are completely consistent to avoid affecting data comparison due to differences in location.

[0119] Image acquisition: The VISIA instrument is used to take full-face / partial images of the marked corner of the eye area. The instrument automatically captures and records relevant image information of the wrinkles around the eyes, generating data that can be used for quantitative analysis.

[0120] Index calculation: The collected images are analyzed by the instrument's software to calculate the proportion of wrinkles at the corners of the eyes (the lower the value, the smaller the area of ​​wrinkles at the corners of the eyes, and the better the anti-wrinkle effect). The mean ± standard error data of each detection point is recorded, and the subject number and group information (experimental side / control side) are linked.

[0121] Data statistics and efficacy assessment:

[0122] Statistical analysis was conducted on the differences in the proportion of canthoplasty and nasolabial fold area between the experimental side at D28 and D0, the differences in the proportion of canthoplasty and nasolabial fold area between the experimental side and the control side at D28, and the differences in the improvement rate (Δ = D28 value - D0 value) of canthoplasty and nasolabial fold area between the experimental side and the control side at D28.

[0123] The test results are shown in Table 4.

[0124] Table 4

[0125]

[0126] From the above appendices, we can see that:

[0127] After 28 days of continuous use of the test products containing the compositions of each embodiment, the skin elasticity (R2), skin firmness (F4), percentage of nasolabial folds, and percentage of crow's feet in the test product area were significantly better than those in the control sample area of ​​the comparative example. Therefore, it is believed that the compositions provided in the embodiments of this application have anti-wrinkle and firming effects.

[0128] 4. Whitening efficacy tests of the compositions in each embodiment and comparative example.

[0129] The skin brightening effect was verified through a two-dimensional approach: VISIA facial image analysis and subjective evaluation by the subjects.

[0130] Thirty healthy men and women aged 35-60 years with a need to improve dull skin tone were selected. The product was applied to the entire face for 28 days (D0 was the initial testing day, and D28 was the final testing day). The product was applied twice a day (once in the morning and once in the evening). An appropriate amount was taken into the palm of the hand and then evenly applied to the face, following the usual skincare routine. Participants were required to fill out a product usage diary to record their daily usage. The diary was collected during the follow-up visit on D28.

[0131] The participants were randomly divided into 5 groups, with 6 people in each group. (The 5 groups were designated as Group 1, Group 2, Group 3, Group 4, and Group 5 respectively; each group used the samples from Example 1, Example 2, Example 3, Example 4, and Comparative Example 1. All 6 volunteers in each group used the same sample from either Example 1 or Comparative Example 1, and the average value was taken).

[0132] This product does not have a control group; it uses a "self-before-and-after comparison" design to compare skin tone changes before and after use.

[0133] The entire process was conducted in a constant temperature and humidity environment (21℃±1℃, 50% RH±10%). Before each test, the subjects were required to cleanse their entire face with a facial cleanser, dry their skin with a tissue, and then sit quietly in the above environment for 30 minutes to eliminate the influence of the environment and cleansing procedures on the skin condition and ensure stable test data.

[0134] Set two key time points to focus on the comparison of skin tone changes before and after use:

[0135] D0 (baseline period): Before using the product, the baseline values ​​of VISIA skin radiance and skin evenness on the whole face were collected as a reference for subsequent comparison;

[0136] D28 (Endpoint Period): After 28 days of continuous product use, the above two instrument indicators were repeatedly collected from the entire face under the same environment and operating procedures, and subjective assessments of the subjects were carried out simultaneously.

[0137] Staff members used the VISIA instrument to photograph the subject's entire face, capturing image information such as skin texture and luster distribution. The instrument automatically generated raw image data. The VISIA software was used to perform quantitative analysis on the collected full-face images, calculate the mean ± standard error of skin luster (expressed as a percentage) and skin evenness (expressed as a numerical value), and store the data.

[0138] Subjective assessment process: During the D28 test, subjects filled out a self-assessment questionnaire while sitting quietly for 30 minutes. The questionnaire used a 5-point scale (1 point for "strongly disagree", 2 points for "disagree", 3 points for "neutral", 4 points for "agree", and 5 points for "strongly agree"). Subjects scored on two indicators: "I feel that my facial skin has become brighter after using the product" and "My dullness has improved after using the product". The percentage of subjects who scored ≥4 points was counted (the rate of agreement).

[0139] Data statistics and efficacy assessment:

[0140] The improvement rate of skin gloss over 28 days was calculated using the following formula: Improvement rate of skin gloss = (Skin gloss on day 28 of the experiment / Skin gloss before the experiment) / Skin gloss before the experiment × 100%;

[0141] The 28-day skin evenness improvement rate was calculated using the following formula: Skin evenness improvement rate = (Skin evenness before experiment / Skin evenness on day 28 of experiment) / Skin evenness before experiment × 100%.

[0142] The test results are shown in Table 5.

[0143] Table 5

[0144]

[0145]

[0146] Note in Table 5: Measurement value: The lower the VISIA skin tone evenness value, the more even the skin tone.

[0147] On a subjective level, the approval rate for "improved facial skin radiance" and "improved dullness" both reached 100% (P<0.001), and the subjective feelings were consistent with the instrument data, further verifying the brightening effect.

[0148] Table 6 Evaluation results of subjects using the test product continuously for 28 days

[0149]

[0150] Note in Table 6: 1. Evaluation indicators: 1 point is "strongly disagree", 2 points is "disagree", 3 points is "neutral", 4 points is "agree", and 5 points is "strongly agree".

[0151] The test data above show that the improvement rate of skin gloss in the samples of Examples 1-4 is significantly higher than that in Comparative Example 1; this indicates that the solution of this application can effectively improve skin gloss.

[0152] The above description is merely a preferred embodiment of this application and is not intended to limit this application. Various modifications and variations can be made to this application by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. A sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects, characterized in that, The sialic acid composition includes: The composition contains chrysanthemum extract and sialic acid; wherein the mass ratio of sialic acid to chrysanthemum extract is 0.5:1 to 1:2.

5.

2. The sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects according to claim 1, characterized in that, The amount of the chrysanthemum extract added to the composition is 2% to 5% by weight. Optionally, the amount of sialic acid added to the composition is 1% to 2% by weight.

3. The sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects according to claim 1, characterized in that, The composition further includes at least one of the following: carnosine, conocycline, ergothioneine, acetyl hexapeptide-8, and caffeine; Optionally, the amount of carnosine added to the composition is 0.1% to 1% by weight. Optionally, the amount of conocycline added to the composition is 3% to 5% by weight. Optionally, the amount of ergothionein added to the composition is 0.01% to 0.05% by weight. Optionally, the amount of acetyl hexapeptide-8 added to the composition is 0.05% to 0.08% by weight. Optionally, the caffeine content in the composition is 0.5% to 1% by weight.

4. The sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects according to claim 1, characterized in that, The sialic acid composition comprises, by weight percentage: 2-5% chrysanthemum extract, 1-2% sialic acid, 0.1-1% carnosine, 3-5% conocycline, 0.01-0.05% ergothioneine, 0.05-0.08% acetyl hexapeptide-8, 0.5%-1% caffeine, 5-15% moisturizer, 0.1-1% antioxidant, 0.1-1% thickener, 5-25% emollient, 1-5% emulsifier, 0.05-0.5% pH adjuster, 0.01-0.1% chelating agent, and the balance being water.

5. The sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects according to claim 4, characterized in that, The moisturizer includes at least one of glycerin, butylene glycol, 1,3-propanediol, or 1,2-hexanediol.

6. The sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects according to claim 4, characterized in that, The antioxidant includes at least one of p-hydroxyacetophenone or tocopheryl acetate.

7. The sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects according to claim 4, characterized in that, The thickener includes: ammonium acryloyldimethyl taurate / VP copolymer.

8. The sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects according to claim 4, characterized in that, The emollients include at least one of the following: shea butter, squalane, caprylic / capric triglyceride, polydimethylsiloxane, or cetearyl alcohol.

9. The sialic acid composition with firming, wrinkle-reducing, and skin-brightening effects according to claim 4, characterized in that, The emulsifier includes at least one of PEG-40 stearate, PEG-100 stearate, or glyceryl stearate; Optionally, the pH adjuster includes arginine; Optionally, the chelating agent includes disodium EDTA.

10. A cosmetic product, characterized in that, The cosmetic product includes the sialic acid composition according to any one of claims 1-9, which has the effects of firming, reducing wrinkles, and brightening skin tone.

Images